1-15 of 15
Charles J. Sherr
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Ruxolitinib in Combination with Dasatinib and Dexamethasone Is an Active and Well-Tolerated Chemotherapy-Sparing Oral Induction Regimen for Adults with Philadelphia Chromosome-Positive ALL: Results of a Phase I Trial

Mark Blaine Geyer, MD, Patrick W. Burke, MD, Amber C. King, PharmD, BCOP, Michael J. Mauro, MD, Martin S. Tallman, MD, Ross L. Levine, MD, Charles J. Sherr, MD PhD, Dan Douer, MD, Jae H. Park, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2692.
https://doi.org/10.1182/blood-2018-99-110537
Published: 2018
Journal Articles

Janus kinase inhibition by ruxolitinib extends dasatinib- and dexamethasone-induced remissions in a mouse model of Ph+ ALL

Iris Appelmann, Cory D. Rillahan, Elisa de Stanchina, Gregory Carbonetti, Chong Chen, Scott W. Lowe, Charles J. Sherr
Journal: Blood
Blood (2015) 125 (9): 1444–1451.
https://doi.org/10.1182/blood-2014-09-601062
Published: 2015
Includes: Supplemental data
Journal Articles

Prevention Of Minimal Residual Disease In Ph+ ALL

Iris Appelmann, MD, Elisa DeStanchina, PhD, Gregory Carbonetti, BS, Chong Chen, PhD, Scott W. Lowe, PhD, Charles J. Sherr, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 1265.
https://doi.org/10.1182/blood.V122.21.1265.1265
Published: 2013
Journal Articles

Host Thiopurine Methyltransferase Status Affects Mercaptopurine Antileukemic Effectiveness

Laura B. Ramsey, PhD, Laura Janke, DVM, PhD, Mathew Edick, PhD, Cheng Cheng, PhD, Richard T Williams, MBBS, PhD, Charles J. Sherr, MD, PhD, William E. Evans, PharmD, Mary V. Relling, PharmD
Journal: Blood
Blood (2012) 120 (21): 3560.
https://doi.org/10.1182/blood.V120.21.3560.3560
Published: 2012
Journal Articles

Functional interactions between Lmo2, the Arf tumor suppressor, and Notch1 in murine T-cell malignancies

Louise M. Treanor, Emmanuel J. Volanakis, Sheng Zhou, Taihe Lu, Charles J. Sherr, Brian P. Sorrentino
Journal: Blood
Blood (2011) 117 (20): 5453–5462.
https://doi.org/10.1182/blood-2010-09-309831
Published: 2011
Includes: Supplemental data
Journal Articles

Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome–positive acute lymphoblastic leukemia

Nidal Boulos, Heather L. Mulder, Christopher R. Calabrese, Jeffrey B. Morrison, Jerold E. Rehg, Mary V. Relling, Charles J. Sherr, Richard T. Williams
Journal: Blood
Blood (2011) 117 (13): 3585–3595.
https://doi.org/10.1182/blood-2010-08-301267
Published: 2011
Includes: Supplemental data
Journal Articles

Developmentally Restricted Protection From Notch1-Induced T Cell Acute Lymphoblastic Leukemia by the Arf Tumor Suppressor.

Emmanuel Volanakis, MD, Richard T Williams, MD, PhD, Charles J. Sherr, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 143.
https://doi.org/10.1182/blood.V114.22.143.143
Published: 2009
Journal Articles

Stage-specific Arf tumor suppression in Notch1 -induced T-cell acute lymphoblastic leukemia

Emmanuel J. Volanakis, Richard T. Williams, Charles J. Sherr
Journal: Blood
Blood (2009) 114 (20): 4451–4459.
https://doi.org/10.1182/blood-2009-07-233346
Published: 2009
Includes: Supplemental data
Journal Articles

Acquired Bcr-Abl Kinase Domain Mutations Are Not Responsible for Persistence of Dasatinib-Refractory Disease in Murine Ph+ ALL

Nidal Boulos, PhD, Charles J. Sherr, MD, PhD, Richard T Williams, MD, PhD
Journal: Blood
Blood (2008) 112 (11): 2924.
https://doi.org/10.1182/blood.V112.11.2924.2924
Published: 2008
Journal Articles

Ultra-High Resolution Analysis of Genomic Alterations in High-Risk Acute Lymphoblastic Leukemia.

Charles G Mullighan, MBBS(Hons), MSc, MD, Letha A. Phillips, BS, Lesli A. Kiedrowski, Jing Ma, PhD, Richard T. Williams, MD, PhD, Sheila A. Shurtleff, Charles J. Sherr, MD, PhD, James R. Downing, MD
Journal: Blood
Blood (2008) 112 (11): 2053.
https://doi.org/10.1182/blood.V112.11.2053.2053
Published: 2008
Journal Articles

Cytokine-Dependent Imatinib Resistance in Mouse Bcr-Abl(+), Arf -Null Lymphoblastic Leukemia.

Richard T. Williams, MD, PhD, Willem den Besten, PhD, Nidal Boulos, PhD, Charles J. Sherr, MD, PhD
Journal: Blood
Blood (2007) 110 (11): 2632.
https://doi.org/10.1182/blood.V110.11.2632.2632
Published: 2007
Journal Articles

Inactivation of the Arf Tumor Suppressor in Mouse BCR-ABL(+) B Cells Greatly Increases the Frequency of Leukemia-Initiating Cells and Confers Imatinib Resistance In Vivo .

Richard T. Williams, MD, PhD, Charles J. Sherr, MD PhD
Journal: Blood
Blood (2006) 108 (11): 385.
https://doi.org/10.1182/blood.V108.11.385.385
Published: 2006
Journal Articles

Regulation of the Arf tumor suppressor in Eμ- Myc transgenic mice: longitudinal study of Myc-induced lymphomagenesis

Brief Report
David Bertwistle, Charles J. Sherr
Journal: Blood
Blood (2006) 109 (2): 792–794.
https://doi.org/10.1182/blood-2006-07-033985
Published: 2006
Journal Articles

Genetic Interaction of the BCR-ABL Oncogene and the ARF Tumor Suppressor in Ph+ Lymphoid Leukemia.

Richard T. Williams, MD, PhD, Martine F. Roussel, PhD, Charles J. Sherr, MD, PhD
Journal: Blood
Blood (2005) 106 (11): 240.
https://doi.org/10.1182/blood.V106.11.240.240
Published: 2005
Journal Articles

Features of Macrophage Differentiation Induced by p19 INK4d , a Specific Inhibitor of Cyclin D–Dependent Kinases

Masashi Adachi, Martine F. Roussel, Karin Havenith, Charles J. Sherr
Journal: Blood
Blood (1997) 90 (1): 126–137.
https://doi.org/10.1182/blood.V90.1.126
Published: 1997